Spyre Therapeutics, Inc.

SYRE · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income-$11-$37-$45-$56
Dep. & Amort.$0$0$0$0
Deferred Tax$0$0$0$0
Stock-Based Comp.$0$9$9$9
Change in WC$6-$9-$1$11
Other Non-Cash-$32-$10-$5-$1
Operating Cash Flow-$37-$47-$41-$37
Investing Activities
PP&E Inv.$0$0$0$0
Net Acquisitions$0$0$0$0
Inv. Purchases-$74-$35-$71-$233
Inv. Sales/Matur.$99$107$71$63
Other Inv. Act.$0$7$0$0
Investing Cash Flow$25$79-$0-$171
Financing Activities
Debt Repay.$0$0$0$0
Stock Issued$0$1$0$225
Stock Repurch.$0$0-$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$5$0$0$1
Financing Cash Flow-$5$1$0$226
Forex Effect$0$0$0-$0
Net Chg. in Cash-$17$33-$41$18
Supplemental Information
Beg. Cash$82$48$89$72
End Cash$65$82$48$89
Free Cash Flow-$37-$47-$41-$37
Spyre Therapeutics, Inc. (SYRE) Financial Statements & Key Stats | AlphaPilot